Source comparison
Thymosin Alpha-1 COVID Protocol Comparison
Mechanism Activates T-cell differentiation and balances cytokine production via TLR signaling Suppresses inflammatory cytokines (IL-6, TNF-alpha) and immune cell activation Neutralizes SARS-CoV-2 spike protein, preventing viral entry into cells Inhibits viral
This comparison does not assign a generated winner or score.
- Mechanism
- Activates T-cell differentiation and balances cytokine production via TLR signaling
- Suppresses inflammatory cytokines (IL-6, TNF-alpha) and immune cell activation
- Neutralizes SARS-CoV-2 spike protein, preventing viral entry into cells
- Inhibits viral RNA polymerase, blocking replication
- Thymosin targets immune restoration; others target inflammation or viral load
- Primary Indication
- Moderate-severe COVID with lymphopenia (lymphocyte count <1,000/µL)
- Severe COVID requiring oxygen or mechanical ventilation
- Mild-moderate COVID in high-risk patients within 10 days of symptom onset
- Hospitalized patients requiring supplemental oxygen
- Thymosin addresses immune dysfunction, not viral suppression
- Dosing Schedule
- 1.6mg subcutaneous twice weekly for 2 weeks (4–6 doses total)
- 6mg oral or IV daily for up to 10 days
- Single 700mg IV infusion within 3 days of symptom onset
- 200mg IV loading dose, then 100mg daily for 5–10 days
- Thymosin requires consistent dosing; others are single-dose or daily
- Mortality Reduction (RCT Data)
- 31–47% relative risk reduction in severe cases
- 17–22% reduction in oxygen-dependent patients
- 70% reduction in hospitalization when used early (pre-Delta variant)
- 23% reduction in time to recovery; no mortality benefit shown
- Thymosin outperforms in lymphopenic populations
- Adverse Events
- Minimal. Injection site pain in 8–12% of patients; no serious AEs reported
- Hyperglycemia (40%), secondary infections (15–20%), psychiatric effects (5–8%)
- Infusion reactions (5%), anaphylaxis (rare, <1%)
- Elevated liver enzymes (8–12%), nausea (10%)
- Thymosin has the cleanest safety profile among immune modulators
- Cost (per treatment course)
- $180–$320 for 6 doses (research-grade; not FDA-approved for clinical use)
- $30–$50 for 10-day course (generic dexamethasone)
- $2,100 per infusion (emergency use authorization pricing)
- $3,120 for 5-day course (branded Veklury)
- Thymosin is mid-range; corticosteroids are cheapest